Objective:

The article examines the objective, findings, and clinical context described in Optimizing aztreonam/ceftazidime-avibactam therapy for difficult-to-treat Stenotrophomonas maltophilia pneumonia: roles of continuous infusion and therapeutic drug monitoring.

Approach:

• Retrospective cohort: Mokrani et al. reported outcomes of difficult-to-treat S. maltophilia pneumonia in ICU patients; the cohort was underpowered to establish differences among individual antimicrobials.
• Single-patient report: In an 11-year-old with cystic fibrosis, TDM identified inadequate initial aztreonam and CAZ/AVI exposure. CI and TDM-guided dose changes achieved 100% fT > MIC target attainment.
• Case series: Goncette et al. retrospectively assessed CI CAZ/AVI with ceftazidime TDM in 10 patients, using a target of plasma and/or infection-site concentrations at least 4–5 times the MIC.

Key Findings:

• In Mokrani et al., tigecycline use was associated with higher mortality; CAZ/AVI and colistin showed favourable but statistically non-significant trends.
• In the 10-patient CAZ/AVI case series, clinical cure occurred in 80%, microbiological eradication in 90%, and 30-day mortality was 10%. Target concentrations were reached in all plasma assessments and 87.5% of infection-site assessments.
• Only two patients in the case series required TDM-based dose modification. The cohort mainly involved multidrug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae, not S. maltophilia.
• Ceftazidime TDM alone does not establish adequate exposure to avibactam; the components have different pharmacodynamic targets.

Interpretation:

The cited reports indicate that antimicrobial selection may not ensure adequate drug exposure and that TDM can identify inadequate concentrations and guide dose adjustment. They do not establish clinical superiority of CAZ/AVI, or clinical benefit of CI and TDM for S. maltophilia pneumonia.

Limitations:

• The Mokrani cohort lacked sufficient power to determine differences among individual antimicrobials and did not provide detailed patient-level dosing, infusion, dose-adjustment, or TDM data.
• The single-patient report cannot demonstrate clinical superiority.
• The CAZ/AVI case series was small and largely involved pathogens other than S. maltophilia.
• TDM in the case series assessed ceftazidime, not avibactam; infection-site concentrations were inferred from published penetration ratios rather than measured directly.

Conclusion:

The article calls for prospective studies reporting patient-specific dosing and infusion methods, pathogen-specific MICs, component-level PK/PD target attainment, and clinical outcomes to determine whether CI and TDM-guided CAZ/AVI optimization improves outcomes in critically ill patients with difficult-to-treat S. maltophilia pneumonia.

Sources:

• Mokrani et al., multinational retrospective cohort study
• Cowart and Ferguson, single-patient report
• Goncette et al., retrospective case series